U.S., Europe Still Far Apart After Talks on Space Station

LONDON—The United States and its European partners remain far apart on how the planned space station should be managed after three days of talks late last month in Paris. "There was no evolution in the U.S. position," said Jean Arets, head of international programs for the 13-member European Space Agency. "It is difficult to know where we go from here." The original timetable for the manned station, which also involves Japan and Canada, called for all partners to agree by this summer on th

Written byPeter Marsh
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"There was no evolution in the U.S. position," said Jean Arets, head of international programs for the 13-member European Space Agency. "It is difficult to know where we go from here."

The original timetable for the manned station, which also involves Japan and Canada, called for all partners to agree by this summer on the role each would play in building and managing the project. But a major stumbling block arose in December when the United States asserted its right to use the station for military research, as well as to cast a decisive vote on the work to be carried out in the various parts of the space station.

The station's cost—itself an increasingly contentious issue—is now an estimated $14 to $16 billion, with the United States putting up three-fourths of the total. The research component of the station is considerable, with experiments planned in such areas as materials ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies